<DOC>
	<DOCNO>NCT01932385</DOCNO>
	<brief_summary>Due HBV HCV infection , 55 % hepatocellular carcinoma patient happen China . Among , 10 % patient diagnose early stage . Sorafenib increase PFS OS advance hepatocellular carcinoma patient liver function Child-Pugh class A patient , result Child-Pugh class B patient unclear .</brief_summary>
	<brief_title>Sorafenib Liver Function Impaired Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>pathological cytological confirm advanced hepatocellular carcinoma 18 year 80 year liver function ChildPugh class B BCLC stage B C estimate life time 2 month longer previous target therapy allergy Sorafenib Uncontrolled Bleeding diarrhea eligible locoregional treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Best supportive care</keyword>
	<keyword>Survival</keyword>
</DOC>